Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Liposomal irinotecan in metastatic pancreatic adenocarcinoma in Asian patients: Subgroup analysis of the NAPOLI‐1 study
Yung‐Jue Bang, Chung‐Pin Li, Kyung‐Hun Lee, et al.
Cancer Science (2019) Vol. 111, Iss. 2, pp. 513-527
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study
Changhoon Yoo, Kyu‐pyo Kim, Jae Ho Jeong, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 11, pp. 1560-1572
Closed Access | Times Cited: 169
Treatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer
Jaewon Hyung, Il Hwan Kim, Kyu‐pyo Kim, et al.
JAMA Oncology (2023) Vol. 9, Iss. 5, pp. 692-692
Closed Access | Times Cited: 44
Liposomal Irinotecan: A Review in Metastatic Pancreatic Adenocarcinoma
James E. Frampton
Drugs (2020) Vol. 80, Iss. 10, pp. 1007-1018
Open Access | Times Cited: 76
Nanoparticles in the diagnosis and treatment of cancer metastases: Current and future perspectives
Mangala Hegde, Nikunj Naliyadhara, Jyothsna Unnikrishnan, et al.
Cancer Letters (2023) Vol. 556, pp. 216066-216066
Closed Access | Times Cited: 38
Safety and Efficacy of CT041 in Patients With Refractory Metastatic Pancreatic Cancer: A Pooled Analysis of Two Early-Phase Trials
Changsong Qi, Panpan Zhang, Chang Liu, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 21, pp. 2565-2577
Closed Access | Times Cited: 10
Which test for crossing survival curves? A user’s guideline
Ina Dormuth, Tiantian Liu, Jin Xu, et al.
BMC Medical Research Methodology (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 38
Patient‐derived tumor organoids predict responses to irinotecan‐based neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer
Tao Lv, Lijun Shen, Xiaoya Xu, et al.
International Journal of Cancer (2022) Vol. 152, Iss. 3, pp. 524-535
Closed Access | Times Cited: 21
Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma
Changhoon Yoo, Jaewon Hyung, Stephen L. Chan
Liver Cancer (2023) Vol. 13, Iss. 2, pp. 119-135
Open Access | Times Cited: 11
Liposomal irinotecan for previously treated patients with biliary tract cancer: A pooled analysis of NIFTY and NALIRICC trials
Changhoon Yoo, Anna Saborowski, Jaewon Hyung, et al.
Journal of Hepatology (2025)
Open Access
Validation of a Prognostic Nomogram for Patients with Metastatic Pancreatic Cancer Treated with Nanoliposomal Irinotecan as Second-Line Therapy
Yi‐Ping Hung, Tai-Jan Chiu, Yen-Yang Chen, et al.
Cancer Control (2025) Vol. 32
Open Access
Phase 1/2 Study of Liposomal Irinotecan Plus S-1 for Metastatic Pancreatic Cancer Refractory to Gemcitabine-based Treatment
Hiroshi Imaoka, Masafumi Ikeda, Masato Ozaka, et al.
European Journal of Cancer (2025) Vol. 222, pp. 115424-115424
Closed Access
The Impact of Liposomal Irinotecan on the Treatment of Advanced Pancreatic Adenocarcinoma: Real-World Experience in a Taiwanese Cohort
Yung‐Yeh Su, Nai‐Jung Chiang, Hui‐Jen Tsai, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 25
Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study
Se Jun Park, Hyunho Kim, Kabsoo Shin, et al.
BMC Cancer (2021) Vol. 21, Iss. 1
Open Access | Times Cited: 20
Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of pancreatic cancer
Jiujie Cui, Jiao Feng, Qi Li, et al.
Journal of the National Cancer Center (2022) Vol. 2, Iss. 4, pp. 205-215
Open Access | Times Cited: 14
Treatment Effect and Safety of Nanoliposomal Irinotecan with Fluorouracil and Folinic Acid after Gemcitabine-Based Therapy in Patients with Advanced Pancreatic Cancer: A Multicenter, Prospective Observational Study
Masami Miki, Nao Fujimori, Keijiro Ueda, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 17, pp. 5084-5084
Open Access | Times Cited: 14
Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer
Yung‐Yeh Su, Nai‐Jung Chiang, Yi‐Hsin Yang, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1008-1008
Open Access | Times Cited: 7
Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)
Yinmo Yang, Xueli Bai, Dapeng Bian, et al.
Journal of Pancreatology (2021) Vol. 4, Iss. 2, pp. 49-66
Open Access | Times Cited: 16
Lipid-based Nanoparticles for the Targeted Delivery of Anticancer Drugs: A Review
Mehrdad Moosazadeh Moghaddam, Hamed Khodaverdi, Maryam Shokrian Zeini, et al.
Current Drug Delivery (2022) Vol. 19, Iss. 10, pp. 1012-1033
Closed Access | Times Cited: 11
Second-line and third-line therapy with nanoliposomal irinotecan (nal-IRI) in pancreatic cancer: a single-center experience and review of literature
Christian Möhring, Freddy José Frontado Graffe, Alexandra Bartels, et al.
Journal of Gastrointestinal Oncology (2023) Vol. 14, Iss. 1, pp. 352-365
Open Access | Times Cited: 6
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
Yung‐Yeh Su, N-J Chiang, J S Chang, et al.
ESMO Open (2022) Vol. 8, Iss. 1, pp. 100746-100746
Open Access | Times Cited: 9
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
Yung‐Yeh Su, Nai‐Jung Chiang, Tai‐Jan Chiu, et al.
Biomedical Journal (2023) Vol. 47, Iss. 3, pp. 100696-100696
Open Access | Times Cited: 5
Nanoliposomal irinotecan with 5-fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy: A real-world experience
Hung-Yuan Yu, Chun-Yang Lee, Le-Gin Lin, et al.
Journal of the Chinese Medical Association (2021) Vol. 85, Iss. 1, pp. 42-50
Open Access | Times Cited: 12
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
Tai‐Jan Chiu, Yung‐Yeh Su, Shih‐Hung Yang, et al.
Therapeutic Advances in Medical Oncology (2021) Vol. 13
Open Access | Times Cited: 11
Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101)
Kazuaki Harada, T. Yamamura, Osamu Muto, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 4, pp. 1596-1596
Open Access | Times Cited: 4
Prior irinotecan exposure does not preclude benefit to liposomal irinotecan in patients with metastatic pancreatic ductal adenocarcinoma
Kenneth H. Yu, Paul Cockrum, Andy Surinach, et al.
Cancer Medicine (2023) Vol. 12, Iss. 8, pp. 9496-9505
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top